Skip to Main Content

The Alabama Board of Pharmacy is weighing whether to renew a permit for Sun Pharmaceuticals (SUNPHARMA) to distribute its medicines in the state after discovering the company was shipping products after its permit expired nearly two years ago, the latest in a growing number of concerning business practices at one of the world’s largest generic drug makers.

A November hearing is scheduled to review an application that Sun Pharma has filed for a new permit, although ongoing settlement talks are under way, according to James Ward, an attorney who represents the board. He did not respond to a question concerning any penalties that Sun may face for distributing medicines, including a generic version of the oxycodone painkiller, without a permit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!